Gilead Sciences is already underway with a phase III study of idelalisib in patients with advanced CLL. The drug is also being studied in indolent non-Hodgkins lymphoma.
Idelalisib works by blocking a protein known as PI3K-delta which is critical for tumor cell growth. PI3K inhibition is a hot molecular target in cancer drug research, being pursued by multiple companies including Infinity Pharmaceuticals (INFI - Get Report), Roche (RHHBY), Novartis (NVS), TG Therapeutics (TGTX) and Oncothyreon (ONTY), according to BioMedTracker.
Investors have been even more excited about the strong efficacy results posted by Pharmacyclics' ibrutinib, which blocks a related cell-growth signal known as Bruton's Tyrorisine Kinase (BTK.)
-- Reported by Adam Feuerstein in Boston.Follow @AdamFeuerstein
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts